<DOC>
	<DOCNO>NCT01292694</DOCNO>
	<brief_summary>The purpose study test hypothesis angiotensin II play role supine hypertension primary autonomic failure . To determine contribution angiotensin II renin blood pressure regulation autonomic failure , patient multiple system atrophy [ MSA ] pure autonomic failure [ PAF ] supine hypertension undergo medication test angiotensin II receptor blocker losartan . The investigator compare biochemical hemodynamic effect MSA PAF patient . In subset patient , investigator also give ACE inhibitor captopril . Our primary endpoint change plasma renin activity , subsequent component circulate renin-angiotensin system , response angiotensin II blockade . Our secondary outcome change hemodynamic measure administration drug .</brief_summary>
	<brief_title>Contribution Angiotensin II Supine Hypertension Autonomic Failure</brief_title>
	<detailed_description>Primary autonomic failure disable condition characterize orthostatic hypotension . It less well appreciate least 50 % patient high blood pressure lie [ supine hypertension ] . The mechanisms underlying supine hypertension autonomic failure remain poorly understood . The hypertension MSA patient may explain residual sympathetic tone , possibly act hypersensitive adrenoreceptors unrestrained lack baroreflex modulation . In contrast , hypertension PAF associate increase vascular resistance absence residual sympathetic tone . However , factor drive elevation either sympathetic vascular tone patient remain unclear . The investigator hypothesize angiotensin II , hormone widely implicate blood pressure regulation , play role supine hypertension autonomic failure . To determine contribution angiotensin II renin blood pressure regulation autonomic failure , investigator administer angiotensin II receptor blocker losartan MSA PAF patient supine hypertension . The primary endpoint change plasma renin activity , subsequent component circulate renin-angiotensin system , response angiotensin II blockade . The secondary outcome decrease blood pressure change heart rate , cardiac output , stroke volume systemic vascular resistance administration drug . Subjects study 2 separate day , one oral administration placebo losartan [ 50 mg ] . The order administration randomize single-blind manner . The investigator collect blood sample every 2 hour administration 6 hour determine angiotensin II regulate plasma renin activity , component circulate renin-angiotensin system , autonomic failure . The investigator also obtain hemodynamic measurement every 1 hour ( blood pressure heart rate ) 2 hour ( cardiac output , stroke volume systemic vascular resistance ) drug administration . In subset patient investigator also administer ACE inhibitor captopril [ 50 mg ] separate study day use method . Captopril less specific assess role angiotensin II hypertension . However , may provide important information mechanism angiotensin II formation patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Pure Autonomic Failure</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Captopril</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Patients autonomic failure exhibit supine hypertension hospital already participate study `` The Evaluation Treatment Autonomic Failure [ IRB # 000814 ] Supine hypertension , define systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mm Hg Males female race , 18 85 year age Able willing provide inform consent understanding may withdraw consent time without prejudice future medical care All medical student Pregnant woman Patients history angioedema Patients know allergy ACE inhibitor angiotensin receptor blocker Highrisk patient [ e.g . heart failure , symptomatic coronary artery disease , liver impairment , history stroke myocardial infarction ] Patients hemoglobin &lt; 10.5 [ hematocrit &lt; 32 ] Inability give , withdraw , informed consent Other factor investigator 's opinion would prevent patient complete protocol include clinically significant abnormality clinical , mental laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>supine hypertension</keyword>
	<keyword>autonomic failure</keyword>
	<keyword>angiotensin</keyword>
	<keyword>losartan</keyword>
	<keyword>captopril</keyword>
</DOC>